​The day will span the full nuclear and medical isotope landscape—from established workhorses like gallium-68, fluorine-18, and lutetium-177 to an incoming wave of innovative use cases and isotope prominence, each bringing new handling and infrastructure demands—alongside the nuclear and industrial isotopes underpinning advanced manufacturing, national security, and frontier science.

Sessions will move beyond high-level market commentary and into the operational middle ground the industry actually needs: aggregating demand across a 5-10 year horizon, understanding distribution and access bottlenecks, and identifying where private sector and government can work together more effectively—including a candid look at what help, investment, or regulatory clarity industry actually wants from government, if any.

This is a working session, not a trade show. Expect roundtable-style discussion, panels, and small-group working sessions where producers, users, researchers, and federal stakeholders can engage directly on the questions regarding strategic stockpiles, single-isotope facility risk, and whether the industry would benefit from isotope pricing benchmarks.